Get the Stockscreener App
5.53
12.78%
-0.81
Evoke Pharma Inc stock is traded at $5.53, with a volume of 146.37K.
It is down -12.78% in the last 24 hours and up +25.97% over the past month.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
See More
Previous Close:
$6.34
Open:
$5.65
24h Volume:
146.37K
Relative Volume:
0.07
Market Cap:
$8.62M
Revenue:
$8.62M
Net Income/Loss:
$-6.15M
P/E Ratio:
-0.5014
EPS:
-11.03
Net Cash Flow:
$-5.32M
1W Performance:
+8.01%
1M Performance:
+25.97%
6M Performance:
+9.07%
1Y Performance:
+24.83%
1-Day Range:
$5.50
$5.8328
1-Week Range:
$5.00
$7.04
52-Week Range:
$1.94
$12.32
Evoke Pharma Inc Stock (EVOK) Company Profile
Name
Evoke Pharma Inc
Sector
Phone
858-345-1494
Address
420 STEVENS AVENUE, SOLANA BEACH, CA
Compare EVOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVOK
Evoke Pharma Inc
|
5.53 | 8.90M | 8.62M | -6.15M | -5.32M | -11.03 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-22-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-05-19 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-08-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Oct-19-17 | Resumed | FBR & Co. | Buy |
| Mar-16-17 | Reiterated | Rodman & Renshaw | Buy |
| Jan-30-17 | Upgrade | Laidlaw | Neutral → Buy |
| Jan-05-17 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Dec-23-16 | Reiterated | Rodman & Renshaw | Neutral |
| Jul-19-16 | Reiterated | FBR Capital | Outperform |
| Jul-19-16 | Downgrade | Noble Financial | Buy → Hold |
| Jul-18-16 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Mar-16-16 | Initiated | Northland Capital | Outperform |
| Mar-14-16 | Reiterated | Ascendiant Capital Markets | Buy |
| Feb-17-16 | Resumed | FBR Capital | Outperform |
| Dec-03-14 | Reiterated | MLV & Co | Buy |
| Nov-07-14 | Initiated | MLV & Co | Buy |
| Apr-22-14 | Initiated | Laidlaw | Buy |
| Nov-19-13 | Initiated | Aegis Capital | Buy |
View All
Evoke Pharma Inc Stock (EVOK) Latest News
Evoke Pharma Inc. Ranks High in Smart Money TrackerVolume Spike & Weekly Breakout Opportunity Watchlist - classian.co.kr
Can Evoke Pharma Inc. rally from current levelsMarket Risk Report & Real-Time Volume Analysis - Newser
How to build a dashboard for Evoke Pharma Inc. stock2025 Major Catalysts & High Yield Equity Trading Tips - Newser
Can Evoke Pharma Inc. recover in the next quarterJuly 2025 Volume & Fast Exit and Entry Strategy Plans - Newser
Technical signs of recovery in Evoke Pharma Inc.Earnings Overview Report & Fast Gaining Stock Strategy Reports - Newser
What machine learning models say about Evoke Pharma Inc.July 2025 Intraday Action & AI Enhanced Market Trend Forecasts - Newser
Chart based analysis of Evoke Pharma Inc. trendsDip Buying & Advanced Swing Trade Entry Alerts - Newser
Investors Still Aren't Entirely Convinced By Evoke Pharma, Inc.'s (NASDAQ:EVOK) Revenues Despite 31% Price Jump - simplywall.st
Applying Elliott Wave Theory to Evoke Pharma Inc.July 2025 Big Picture & Weekly Top Gainers Alerts - Newser
Evoke Pharma Inc. Sees Relief Buying After Extended DropJuly 2025 Summary & Community Verified Swing Trade Signals - Newser
Momentum divergence signals in Evoke Pharma Inc. chartEarnings Recap Report & Accurate Technical Buy Alerts - Newser
Evoke Pharma Earnings Miss: Revenue Falls Short, Earnings Plunge to -$2.69 EPS Amid Rising Costs - AInvest
Using data filters to optimize entry into Evoke Pharma Inc.2025 Analyst Calls & Consistent Growth Equity Picks - Newser
Evoke Pharma, Inc. (NASDAQ:EVOK) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
Evoke Pharma Reports Q2 2025 Earnings: Loss Widens Despite Revenue Gains; Market Reaction Remains Cautious - AInvest
Backtesting results for Evoke Pharma Inc. trading strategiesTrade Entry Report & Weekly Chart Analysis and Guides - Newser
Is Evoke Pharma Inc. forming a breakout patternQuarterly Profit Review & Daily Profit Focused Stock Screening - newsyoung.net
Evoke Pharma sees FY25 net product sales of approx $16M - MSN
Evoke Pharma Inc. stock trendline breakdownJuly 2025 Fed Impact & AI Powered Market Entry Strategies - Newser
Visualizing Evoke Pharma Inc. stock with heatmapsEntry Point & Free Community Consensus Stock Picks - Newser
Can a trend reversal in Evoke Pharma Inc. lead to recovery2025 Pullback Review & Expert Approved Momentum Ideas - Newser
Using RSI to spot recovery in Evoke Pharma Inc.July 2025 Decliners & Verified Momentum Stock Ideas - Newser
Evoke Pharma Reports 47% Q2 2025 Sales Growth, Raises Full-Year Guidance - AInvest
Evoke Pharma reports Q2 EPS (62c) vs (93c) last year - MSN
How sentiment analysis helps forecast Evoke Pharma Inc.Weekly Trade Analysis & Growth Oriented Trading Recommendations - Newser
Top Risks to Consider Before Buying Evoke Pharma Inc. StockTake Profit & Weekly Watchlist of Top Performers - Newser
Evoke Pharma Posts 47 Percent Q2 Growth - AOL.com
Evoke Pharma Inc. Builds Base for Possible Rebound2025 Major Catalysts & Real-Time Market Sentiment Alerts - kangso.co.kr
Short Interest in Evoke Pharma, Inc. (NASDAQ:EVOK) Decreases By 78.2% - Defense World
Evoke Pharma Reports Strong Q2 2025 Sales Growth - TipRanks
Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Evoke Pharma 2025 Q2 Earnings Mixed Performance with Net Loss Widening - AInvest
Elliott Wave Theory Predicts Pullback in Evoke Pharma Inc.2025 Breakouts & Breakdowns & Long-Term Growth Stock Strategies - newsyoung.net
Evoke Pharma Reports 47% Q2 Growth, Affirms FY Sales Outlook - AInvest
Evoke Pharma Q2 Earnings: Revenue at $3.75M, EPS of 62c - AInvest
RSI Reset May Fuel Rebound in Evoke Pharma Inc.Weekly Market Report & Smart Allocation Stock Reports - beatles.ru
Evoke Pharma, Inc. Confirms Sales Guidance for the Year 2025 - MarketScreener
Evoke Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Evoke Pharma Inc SEC 10-Q Report - TradingView
Gastroparesis Drug Maker Evoke Posts Strong Growth as GIMOTI Adoption Accelerates - Stock Titan
Is Evoke Pharma Inc. trending in predictive chart modelsJuly 2025 Short Interest & Weekly Return Optimization Alerts - Newser
Will Volume Confirm Reversal in Evoke Pharma Inc.July 2025 Market Mood & Fast Gain Stock Trading Tips - sundaytimes.kr
Evoke Pharma Inc Stock (EVOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):